MVRBF Medivir AB - Ordinary Shares - Class B

About MVRBF

Medivir AB engages in the development of pharmaceuticals products. The firm focuses on the discovery and development of transformative active cancer drugs. Its portfolio includes proprietary pipelines such as remetinostat, birinapant, MV-818, MV-828, and MIV-711 projects, and partnership pipeline which covers xerclear and MIV-802 project. The company was founded in 1988 and is headquartered in Huddinge, Sweden.
50

Neutral Sentiment

How do you feel about MVRBF?

Advertisement|Remove ads.